Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

UTMD – Utah Medical Products, Inc.

UTMD — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

3.86

Margin Of Safety %

12

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

64.57

Target Price

65.23

Analyst Recom

1

Performance Q

14.17

Upside

-30.2%

Beta

0.36

Ticker: UTMD




15 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-03UTMD66.85N/AN/A0
2026-03-04UTMD66.18N/AN/A0
2026-03-06UTMD65.29N/AN/A0
2026-03-09UTMD64.25N/AN/A0
2026-03-10UTMD63.95N/AN/A0
2026-03-11UTMD63.71N/AN/A0
2026-03-12UTMD62.6N/AN/A0
2026-03-13UTMD62.64N/AN/A0
2026-03-17UTMD64.78N/AN/A0
2026-03-18UTMD64.75N/AN/A0
2026-03-20UTMD64.11N/AN/A0
2026-03-25UTMD63.44N/AN/A0
2026-03-26UTMD62.52N/AN/A0
2026-03-27UTMD61.54N/AN/A0
2026-03-30UTMD65.06N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
15 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-02UTMD66.93- - -
2026-03-03UTMD66.64- - -
2026-03-04UTMD66.57- - -
2026-03-05UTMD65.71- - -
2026-03-06UTMD65.29- - -
2026-03-09UTMD64.24- - -
2026-03-10UTMD63.99- - -
2026-03-11UTMD63.71- - -
2026-03-12UTMD62.92- - -
2026-03-13UTMD63.27- - -
2026-03-17UTMD64.88- - -
2026-03-18UTMD64.49- - -
2026-03-19UTMD63.95- - -
2026-03-20UTMD64.63- - -
2026-03-23UTMD65.67- - -
2026-03-24UTMD64.21- - -
2026-03-25UTMD64.01- - -
2026-03-26UTMD62.89- - -
2026-03-27UTMD61.85- - -
2026-03-30UTMD64.57- - -
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-02UTMD0.00-1.783.50
2026-03-03UTMD0.00-1.783.50
2026-03-04UTMD0.00-1.783.50
2026-03-05UTMD0.00-1.783.50
2026-03-06UTMD0.00-1.783.50
2026-03-09UTMD0.00-1.783.50
2026-03-10UTMD0.00-1.783.50
2026-03-11UTMD0.00-1.783.71
2026-03-12UTMD0.00-1.783.71
2026-03-13UTMD0.00-1.783.71
2026-03-18UTMD0.00-1.783.71
2026-03-19UTMD0.00-1.783.71
2026-03-20UTMD0.00-1.783.71
2026-03-23UTMD0.00-1.773.71
2026-03-24UTMD0.00-1.773.71
2026-03-25UTMD0.00-1.773.86
2026-03-26UTMD0.00-1.773.86
2026-03-27UTMD0.00-1.773.86
2026-03-30UTMD0.00-1.773.86
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-1.77

Beta

0.36

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

72.35

Quality Score

79

Growth Score

53

Sentiment Score

61

Actual DrawDown %

51.8

Max Drawdown 5-Year %

-55.6

Target Price

65.23

P/E

18.62

Forward P/E

PEG

P/S

5.39

P/B

1.73

P/Free Cash Flow

14.49

EPS

3.48

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

29.3

Relative Volume

1.35

Return on Equity vs Sector %

-17.6

Return on Equity vs Industry %

0.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

UTMD Healthcare
$64.79
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
14/20
Pullback
22/25
Volume
3/15
Valuation
8/20
TP/AR
2/10
Options
0/10
RSI
53.5
Range 1M
18.2%
Sup Dist
3.5%
🚀
Momentum Growth
Ride accelerating trends
N/A
20 /100
WEAK
Momentum
8/25
Growth
4/30
Estimates
3/20
Inst/Vol
5/15
Options
0/10
EPS Yr
0%
EPS NY
0%
52W%
68%
💎
Long-Term Value
Quality companies, undervalued
23 /100
WEAK
🟡 HOLD +7.3% upside
Quality
8/30
Valuation
7/30
Growth
0/25
Stability
8/10
LT Trend
0/5
Upside
+7.3%
Quality
79
MoS
12%
Utah Medical Products, Inc.
Sector: Healthcare
Industry: Medical Instruments & Supplies
Employees: 140
Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
UTMD

Latest News

Caricamento notizie per UTMD
stock quote shares UTMD – Utah Medical Products, Inc. Stock Price stock today
news today UTMD – Utah Medical Products, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch UTMD – Utah Medical Products, Inc. yahoo finance google finance
stock history UTMD – Utah Medical Products, Inc. invest stock market
stock prices UTMD premarket after hours
ticker UTMD fair value insiders trading

ATRI – Atrion Corp.

ATRI — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

2.53

Margin Of Safety %

-2

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

459.92

Target Price

300

Analyst Recom

5

Performance Q

-2.64

Upside

N/A

Beta

0.69

Ticker: ATRI




15 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-03ATRI459.92N/AN/A0
2026-03-04ATRI459.92N/AN/A0
2026-03-06ATRI459.92N/AN/A0
2026-03-09ATRI459.92N/AN/A0
2026-03-10ATRI459.92N/AN/A0
2026-03-11ATRI459.92N/AN/A0
2026-03-12ATRI459.92N/AN/A0
2026-03-13ATRI459.92N/AN/A0
2026-03-17ATRI459.92N/AN/A0
2026-03-18ATRI459.92N/AN/A0
2026-03-20ATRI459.92N/AN/A0
2026-03-25ATRI459.92N/AN/A0
2026-03-26ATRI459.92N/AN/A0
2026-03-27ATRI459.92N/AN/A0
2026-03-30ATRI459.92N/AN/A0
DateSymbolLatestP/C OIP/C VolTotal OI
15 items Current Page1 of 1




No data found




No data found

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

0.69

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

452.44

Quality Score

87

Growth Score

73

Sentiment Score

66

Actual DrawDown %

45.7

Max Drawdown 5-Year %

-66

Target Price

300

P/E

64.5

Forward P/E

PEG

P/S

4.46

P/B

3.39

P/Free Cash Flow

29.24

EPS

7.13

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

6.91

Relative Volume

Return on Equity vs Sector %

-18.1

Return on Equity vs Industry %

-3.7

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

ATRI

Latest News

Caricamento notizie per ATRI
stock quote shares ATRI – Atrion Corp. Stock Price stock today
news today ATRI – Atrion Corp. stock forecast ,stock prediction 2023 2024 2025
marketwatch ATRI – Atrion Corp. yahoo finance google finance
stock history ATRI – Atrion Corp. invest stock market
stock prices ATRI premarket after hours
ticker ATRI fair value insiders trading

ATR – Aptargroup Inc.

ATR — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

2

Margin Of Safety %

11

Put/Call OI Ratio

0.68

EPS Next Q Diff

0.12

EPS Last/This Y

-0.42

EPS This/Next Y

0.85

Price

123.35

Target Price

162.83

Analyst Recom

1.9

Performance Q

0.09

Upside

66.8%

Beta

0.52

Ticker: ATR




15 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-03ATR139.720.750.00489
2026-03-04ATR137.030.750.00488
2026-03-06ATR132.030.745.00500
2026-03-09ATR133.770.748.00502
2026-03-10ATR132.070.810.27508
2026-03-11ATR131.980.70999.99553
2026-03-12ATR128.760.70999.99553
2026-03-13ATR128.860.70999.99553
2026-03-17ATR129.570.600.00519
2026-03-18ATR124.270.600.00517
2026-03-20ATR121.070.590.00518
2026-03-25ATR125.880.690.00463
2026-03-26ATR124.670.690.00463
2026-03-27ATR122.020.690.00463
2026-03-30ATR123.310.680.00466
DateSymbolLatestP/C OIP/C VolTotal OI
15 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-02ATR142.71-3.5-59.25.54
2026-03-03ATR139.80-3.5-64.95.54
2026-03-04ATR137.05-3.5-64.65.54
2026-03-05ATR134.73-3.5-63.55.54
2026-03-06ATR132.00-3.5-64.95.54
2026-03-09ATR133.74-3.5-50.75.54
2026-03-10ATR132.10-3.5-61.55.54
2026-03-11ATR131.93-3.5-56.85.54
2026-03-12ATR128.80-3.5-66.75.54
2026-03-13ATR128.62-3.5-56.95.54
2026-03-17ATR129.51-3.5-54.65.54
2026-03-18ATR124.23-3.5-73.65.54
2026-03-19ATR124.03-3.5-56.85.54
2026-03-20ATR121.05-3.5-66.25.54
2026-03-23ATR124.12-3.5-45.45.54
2026-03-24ATR124.15-3.5-56.05.54
2026-03-25ATR125.77-3.5-50.65.54
2026-03-26ATR124.60-3.8-60.35.54
2026-03-27ATR121.98-3.8-65.55.54
2026-03-30ATR123.35-3.8-51.45.54
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-02ATR-3.69-2.051.85
2026-03-03ATR-3.69-2.051.85
2026-03-04ATR-3.69-2.051.85
2026-03-05ATR-3.69-2.051.85
2026-03-06ATR-3.69-2.051.85
2026-03-09ATR-3.52-2.081.85
2026-03-10ATR-3.52-2.081.85
2026-03-11ATR-3.52-2.082.03
2026-03-12ATR-3.52-2.082.03
2026-03-13ATR-3.15-2.082.03
2026-03-17ATR-3.15-2.112.03
2026-03-18ATR-3.15-2.112.03
2026-03-19ATR-3.15-2.112.03
2026-03-20ATR-3.15-2.112.03
2026-03-23ATR-3.15-2.132.03
2026-03-24ATR-3.15-2.132.03
2026-03-25ATR-3.15-2.132.00
2026-03-26ATR-3.15-2.132.00
2026-03-27ATR-3.15-2.132.00
2026-03-30ATR-3.15-2.132.00
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

1.25

Avg. EPS Est. Current Quarter

1.15

Avg. EPS Est. Next Quarter

1.37

Insider Transactions

-3.15

Institutional Transactions

-2.13

Beta

0.52

Average Sales Estimate Current Quarter

956

Average Sales Estimate Next Quarter

995

Fair Value

136.51

Quality Score

85

Growth Score

74

Sentiment Score

50

Actual DrawDown %

30.7

Max Drawdown 5-Year %

-39.8

Target Price

162.83

P/E

20.97

Forward P/E

19

PEG

2.38

P/S

2.1

P/B

2.97

P/Free Cash Flow

26.51

EPS

5.88

Average EPS Est. Cur. Y​

5.54

EPS Next Y. (Est.)

6.39

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

10.4

Relative Volume

1.08

Return on Equity vs Sector %

-12.7

Return on Equity vs Industry %

5.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

-51.4
ATR Healthcare
$123.36
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
20/20
Pullback
25/25
Volume
4/15
Valuation
18/20
TP/AR
1/10
Options
4/10
RSI
37.4
Range 1M
13.2%
Sup Dist
1.8%
🚀
Momentum Growth
Ride accelerating trends
N/A
36 /100
WEAK
Momentum
13/25
Growth
11/30
Estimates
5/20
Inst/Vol
2/15
Options
5/10
EPS Yr
-2.6%
EPS NY
16.1%
52W%
33%
💎
Long-Term Value
Quality companies, undervalued
48 /100
WEAK
🟢 BUY +50.3% upside
Quality
15/30
Valuation
16/30
Growth
7/25
Stability
7/10
LT Trend
3/5
Upside
+50.3%
Quality
85
MoS
11%
AptarGroup, Inc.
Sector: Healthcare
Industry: Medical Instruments & Supplies
Employees: 14000
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations, as well as closures, such as dispensing and non-dispensing solutions that enable product delivery without removal of the cap and used across various consumer end markets. The company also offers aerosol valves used in pressurized containers and continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications; elastomeric primary packaging components; active material science solutions; and digital health solutions. The company primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
ATR

Latest News

Caricamento notizie per ATR
stock quote shares ATR – Aptargroup Inc. Stock Price stock today
news today ATR – Aptargroup Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ATR – Aptargroup Inc. yahoo finance google finance
stock history ATR – Aptargroup Inc. invest stock market
stock prices ATR premarket after hours
ticker ATR fair value insiders trading

ANIK – Anika Therapeutics Inc.

ANIK — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

5.53

Margin Of Safety %

-33

Put/Call OI Ratio

0.05

EPS Next Q Diff

-0.06

EPS Last/This Y

0.14

EPS This/Next Y

0.15

Price

14.13

Target Price

17

Analyst Recom

1

Performance Q

47.96

Upside

-288.3%

Beta

0.28

Ticker: ANIK




15 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-03ANIK14.430.130.13594
2026-03-04ANIK14.370.130.00617
2026-03-06ANIK14.130.150.00624
2026-03-09ANIK14.960.150.00624
2026-03-10ANIK14.460.150.08647
2026-03-11ANIK14.360.150.08647
2026-03-12ANIK14.310.140.00652
2026-03-13ANIK14.30.140.00652
2026-03-17ANIK14.50.150.00641
2026-03-18ANIK14.130.150.00641
2026-03-20ANIK13.850.16999.99663
2026-03-25ANIK14.540.050.00405
2026-03-26ANIK14.770.050.00405
2026-03-27ANIK14.30.050.00405
2026-03-30ANIK14.120.050.00405
DateSymbolLatestP/C OIP/C VolTotal OI
15 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-02ANIK14.31166.7- -0.13
2026-03-03ANIK14.40166.7- -0.13
2026-03-04ANIK14.36166.7- -0.13
2026-03-05ANIK14.26166.7- -0.13
2026-03-06ANIK14.10166.7- -0.13
2026-03-09ANIK14.98100.0- 0.25
2026-03-10ANIK14.44100.0- 0.25
2026-03-11ANIK14.38100.0- 0.25
2026-03-12ANIK14.29100.0- 0.25
2026-03-13ANIK14.23100.0- 0.25
2026-03-17ANIK14.52100.0- 0.25
2026-03-18ANIK14.11100.0- 0.25
2026-03-19ANIK14.20100.0- 0.25
2026-03-20ANIK13.85100.0- 0.25
2026-03-23ANIK14.27100.0- 0.25
2026-03-24ANIK14.28100.0- 0.25
2026-03-25ANIK14.56100.0- 0.25
2026-03-26ANIK14.76100.0- 0.25
2026-03-27ANIK14.30100.0- 0.25
2026-03-30ANIK14.13100.0- 0.25
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-02ANIK0.000.215.52
2026-03-03ANIK0.000.215.52
2026-03-04ANIK0.000.215.52
2026-03-05ANIK0.000.215.52
2026-03-06ANIK0.000.215.94
2026-03-09ANIK0.000.225.94
2026-03-10ANIK0.000.225.94
2026-03-11ANIK0.000.225.69
2026-03-12ANIK0.000.225.69
2026-03-13ANIK0.000.225.69
2026-03-18ANIK0.000.625.69
2026-03-19ANIK0.000.625.69
2026-03-20ANIK0.000.625.69
2026-03-23ANIK0.000.625.69
2026-03-24ANIK0.000.625.69
2026-03-25ANIK0.000.625.53
2026-03-26ANIK0.000.625.53
2026-03-27ANIK0.000.625.53
2026-03-30ANIK0.000.535.53
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

0.13

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

0.07

Insider Transactions

Institutional Transactions

0.53

Beta

0.28

Average Sales Estimate Current Quarter

28

Average Sales Estimate Next Quarter

29

Fair Value

9.5

Quality Score

41

Growth Score

36

Sentiment Score

53

Actual DrawDown %

70.8

Max Drawdown 5-Year %

-83.2

Target Price

17

P/E

Forward P/E

62.8

PEG

0.93

P/S

1.68

P/B

1.37

P/Free Cash Flow

43.43

EPS

-0.76

Average EPS Est. Cur. Y​

0.25

EPS Next Y. (Est.)

0.4

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-9.64

Relative Volume

0.84

Return on Equity vs Sector %

-35

Return on Equity vs Industry %

-14.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

ANIK Healthcare
$14.13
📉
Swing / Pullback
Buy the dip on strong trends
54 /100
WEAK
Trend
20/20
Pullback
6/25
Volume
7/15
Valuation
13/20
TP/AR
2/10
Options
6/10
RSI
58.5
Range 1M
90.5%
🚀
Momentum Growth
Ride accelerating trends
N/A
47 /100
WEAK
Momentum
13/25
Growth
19/30
Estimates
1/20
Inst/Vol
6/15
Options
8/10
EPS Yr
-104.6%
EPS NY
4600%
52W%
87.1%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🔴 SELL -6.2% upside
Quality
6/30
Valuation
5/30
Growth
13/25
Stability
9/10
LT Trend
4/5
Upside
-6.2%
Quality
41
MoS
-33%
Anika Therapeutics Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 235
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
ANIK

Latest News

Caricamento notizie per ANIK
stock quote shares ANIK – Anika Therapeutics Inc. Stock Price stock today
news today ANIK – Anika Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ANIK – Anika Therapeutics Inc. yahoo finance google finance
stock history ANIK – Anika Therapeutics Inc. invest stock market
stock prices ANIK premarket after hours
ticker ANIK fair value insiders trading

ANGO – Angiodynamic Inc

ANGO — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

4.9

Margin Of Safety %

Put/Call OI Ratio

0.25

EPS Next Q Diff

EPS Last/This Y

0.54

EPS This/Next Y

0.18

Price

10.88

Target Price

19.33

Analyst Recom

1

Performance Q

-17.02

Upside

-315.7%

Beta

0.45

Ticker: ANGO




15 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-03ANGO11.030.180.022400
2026-03-04ANGO10.990.180.002368
2026-03-06ANGO10.820.180.002377
2026-03-09ANGO10.770.180.002398
2026-03-10ANGO110.180.002370
2026-03-11ANGO11.050.180.032420
2026-03-12ANGO10.720.170.002430
2026-03-13ANGO10.710.170.002430
2026-03-17ANGO10.70.180.822417
2026-03-18ANGO10.420.190.832443
2026-03-20ANGO10.420.190.002542
2026-03-25ANGO11.220.260.001884
2026-03-26ANGO11.290.260.051906
2026-03-27ANGO10.930.250.001933
2026-03-30ANGO10.880.250.001934
DateSymbolLatestP/C OIP/C VolTotal OI
15 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-02ANGO11.36-466.7- -0.29
2026-03-03ANGO11.03-466.7- -0.29
2026-03-04ANGO10.99-466.7- -0.29
2026-03-05ANGO10.89-466.7- -0.29
2026-03-06ANGO10.81-466.7- -0.29
2026-03-09ANGO10.77-466.7- -0.29
2026-03-10ANGO11.01-466.7- -0.29
2026-03-11ANGO11.05-466.7- -0.29
2026-03-12ANGO10.72-466.7- -0.29
2026-03-13ANGO10.60-466.7- -0.29
2026-03-17ANGO10.72-466.7- -0.29
2026-03-18ANGO10.42-466.7- -0.29
2026-03-19ANGO10.63-466.7- -0.29
2026-03-20ANGO10.41-466.7- -0.29
2026-03-23ANGO10.70-466.7- -0.29
2026-03-24ANGO10.63-466.7- -0.29
2026-03-25ANGO11.23-466.7- -0.29
2026-03-26ANGO11.27-466.7- -0.29
2026-03-27ANGO10.92-466.7- -0.29
2026-03-30ANGO10.88-466.7- -0.29
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-02ANGO0.44-5.034.66
2026-03-03ANGO0.44-5.034.66
2026-03-04ANGO0.44-5.034.66
2026-03-05ANGO0.44-5.034.66
2026-03-06ANGO0.44-5.034.66
2026-03-09ANGO0.44-5.034.66
2026-03-10ANGO0.44-5.034.66
2026-03-11ANGO0.44-5.035.97
2026-03-12ANGO0.44-5.035.97
2026-03-13ANGO0.44-5.035.97
2026-03-18ANGO0.44-4.955.97
2026-03-19ANGO0.44-4.955.97
2026-03-20ANGO0.44-4.955.97
2026-03-23ANGO0.44-1.415.97
2026-03-24ANGO0.44-1.415.97
2026-03-25ANGO0.44-1.414.90
2026-03-26ANGO0.44-1.414.90
2026-03-27ANGO0.44-1.414.90
2026-03-30ANGO0.44-1.424.90
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.11

Avg. EPS Est. Next Quarter

-0.08

Insider Transactions

0.44

Institutional Transactions

-1.42

Beta

0.45

Average Sales Estimate Current Quarter

76

Average Sales Estimate Next Quarter

80

Fair Value

Quality Score

43

Growth Score

48

Sentiment Score

94

Actual DrawDown %

66

Max Drawdown 5-Year %

-83

Target Price

19.33

P/E

Forward P/E

PEG

P/S

1.46

P/B

2.56

P/Free Cash Flow

EPS

-0.67

Average EPS Est. Cur. Y​

-0.29

EPS Next Y. (Est.)

-0.11

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-9.02

Relative Volume

0.71

Return on Equity vs Sector %

-43.2

Return on Equity vs Industry %

-25.3

EPS 1 7Days Diff

EPS 1 30Days Diff

0.04

EBIT Estimation

ANGO Healthcare
$10.87
📉
Swing / Pullback
Buy the dip on strong trends
62 /100
WATCH
Trend
20/20
Pullback
15/25
Volume
9/15
Valuation
10/20
TP/AR
2/10
Options
6/10
RSI
49.6
Range 1M
82.6%
Sup Dist
0%
🚀
Momentum Growth
Ride accelerating trends
N/A
34 /100
WEAK
Momentum
7/25
Growth
17/30
Estimates
2/20
Inst/Vol
1/15
Options
7/10
EPS Yr
-93.3%
EPS NY
62.1%
52W%
54.9%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +77.8% upside
Quality
5/30
Valuation
14/30
Growth
10/25
Stability
8/10
LT Trend
3/5
Upside
+77.8%
Quality
43
AngioDynamics, Inc.
Sector: Healthcare
Industry: Medical Instruments & Supplies
Employees: 675
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit for use in extracorporeal circulatory support procedures for periods of up to six hours, as well as with other manufacturers' off-the-shelf pump, filter, and reinfusion cannula facilitate venous drainage. It also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, diagnostic and interventional guidewires, and coaxial micro-introducer kits for use in peripheral diagnostic and interventional procedures. In addition, the company provides abscession drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-access kits offer interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero Microwave Tissue Ablation System includes solero microwave generator and the solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
ANGO

Latest News

Caricamento notizie per ANGO
stock quote shares ANGO – Angiodynamic Inc Stock Price stock today
news today ANGO – Angiodynamic Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ANGO – Angiodynamic Inc yahoo finance google finance
stock history ANGO – Angiodynamic Inc invest stock market
stock prices ANGO premarket after hours
ticker ANGO fair value insiders trading

BLCO – Bausch + Lomb Corporation

BLCO — Price & Forward EBITDA
Forward EBITDA (M)

Float Short %

10.56

Margin Of Safety %

Put/Call OI Ratio

0.09

EPS Next Q Diff

-0.16

EPS Last/This Y

EPS This/Next Y

0.29

Price

15.25

Target Price

18.46

Analyst Recom

2.71

Performance Q

-11.18

Upside

-333.9%

Beta

0.69

Ticker: BLCO




15 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-03-03BLCO17.980.110.002645
2026-03-04BLCO18.030.090.003249
2026-03-06BLCO17.030.090.143442
2026-03-09BLCO17.190.090.013450
2026-03-10BLCO17.130.090.013452
2026-03-11BLCO17.50.090.263532
2026-03-12BLCO16.560.090.013598
2026-03-13BLCO16.580.090.013598
2026-03-17BLCO16.70.090.003949
2026-03-18BLCO16.020.090.003984
2026-03-20BLCO15.720.100.024033
2026-03-25BLCO16.010.100.003474
2026-03-26BLCO15.880.090.003664
2026-03-27BLCO15.380.090.013713
2026-03-30BLCO15.250.090.013900
DateSymbolLatestP/C OIP/C VolTotal OI
15 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-03-02BLCO18.39161.0- 0.78
2026-03-03BLCO17.98161.0- 0.78
2026-03-04BLCO18.05181.3- 0.78
2026-03-05BLCO17.59181.3- 0.78
2026-03-06BLCO17.07181.3- 0.78
2026-03-09BLCO17.22181.3- 0.78
2026-03-10BLCO17.14181.3- 0.78
2026-03-11BLCO17.50181.3- 0.78
2026-03-12BLCO16.57181.3- 0.78
2026-03-13BLCO16.21181.3- 0.78
2026-03-17BLCO16.67181.3- 0.78
2026-03-18BLCO16.02181.3- 0.78
2026-03-19BLCO16.16181.3- 0.78
2026-03-20BLCO15.72181.3- 0.78
2026-03-23BLCO15.84181.3- 0.78
2026-03-24BLCO15.71181.3- 0.78
2026-03-25BLCO16.00181.3- 0.78
2026-03-26BLCO15.87181.3- 0.78
2026-03-27BLCO15.38172.6- 0.78
2026-03-30BLCO15.25172.6- 0.78
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-03-02BLCO0.01-0.848.34
2026-03-03BLCO0.01-0.848.34
2026-03-04BLCO0.01-0.848.34
2026-03-05BLCO0.01-0.848.34
2026-03-06BLCO0.01-0.848.34
2026-03-09BLCO0.01-0.818.34
2026-03-10BLCO0.02-0.818.34
2026-03-11BLCO0.02-0.817.01
2026-03-12BLCO0.02-0.817.01
2026-03-13BLCO0.02-0.817.01
2026-03-17BLCO0.02-0.847.01
2026-03-18BLCO0.02-0.847.01
2026-03-19BLCO0.02-0.847.01
2026-03-20BLCO0.02-0.847.01
2026-03-23BLCO0.02-0.847.01
2026-03-24BLCO0.02-0.847.01
2026-03-25BLCO0.02-0.8410.56
2026-03-26BLCO0.02-0.8410.56
2026-03-27BLCO0.02-0.8410.56
2026-03-30BLCO0.02-0.8410.56
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.32

Avg. EPS Est. Current Quarter

0.05

Avg. EPS Est. Next Quarter

0.16

Insider Transactions

0.02

Institutional Transactions

-0.84

Beta

0.69

Average Sales Estimate Current Quarter

1214

Average Sales Estimate Next Quarter

1370

Fair Value

Quality Score

52

Growth Score

69

Sentiment Score

48

Actual DrawDown %

30.5

Max Drawdown 5-Year %

Target Price

18.46

P/E

Forward P/E

14.29

PEG

0.36

P/S

1.06

P/B

0.84

P/Free Cash Flow

EPS

-1.02

Average EPS Est. Cur. Y​

0.78

EPS Next Y. (Est.)

1.07

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-7.06

Relative Volume

1.42

Return on Equity vs Sector %

-33

Return on Equity vs Industry %

-15.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

BLCO Healthcare
$15.26
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
20/20
Pullback
21/25
Volume
3/15
Valuation
13/20
TP/AR
2/10
Options
7/10
RSI
33
Range 1M
5.8%
Sup Dist
0.3%
🚀
Momentum Growth
Ride accelerating trends
N/A
53 /100
WEAK
Momentum
18/25
Growth
17/30
Estimates
5/20
Inst/Vol
3/15
Options
10/10
EPS Yr
52.8%
EPS NY
37.1%
52W%
57.7%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🟢 BUY +109.9% upside
Quality
5/30
Valuation
19/30
Growth
14/25
Stability
3/10
LT Trend
3/5
Upside
+109.9%
Quality
52
Bausch + Lomb Corporation
Sector: Healthcare
Industry: Medical Instruments & Supplies
Employees: 13000
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
BLCO

Latest News

Caricamento notizie per BLCO
stock quote shares BLCO – Bausch + Lomb Corporation Stock Price stock today
news today BLCO – Bausch + Lomb Corporation stock forecast ,stock prediction 2023 2024 2025
marketwatch BLCO – Bausch + Lomb Corporation yahoo finance google finance
stock history BLCO – Bausch + Lomb Corporation invest stock market
stock prices BLCO premarket after hours
ticker BLCO fair value insiders trading
No more stocks to show